• AZ/MSD pursue wider indication for Lynparza on trial success pharmatimes
    July 04, 2018
    AstraZeneca and MSD have unveiled trial results showing that Lynparza significantly extended the time patients with ovarian cancer lived without their disease worsening in the first-line maintenance setting, which could significantly expand the drug’s rea
PharmaSources Customer Service